Prostate Hypoxia - TIC

NCT02095249 | Active Not Recruiting

• 1 other identifier: UHN REB 13-7172-C
• Study Type: interventional
• Target: 39
• Locations: 1 country
• Sites: 1

Brief Summary

Prostate cancer is the most commonly diagnosed form of cancer in Canadian men. In 2006, greater than 250,000 men were diagnosed with prostate cancer in the United States and Canada with more than 32,000 men dying of their disease. Using the prognostic variables of T-category, the serum prostate specific antigen (PSA), and the pathologic Gleason score (GS), men with localized prostate cancer are placed in low, intermediate and high-risk groupings. Usually this is treated with surgery, radiation therapy, hormone therapy and/or watchful waiting (also known as active surveillance). While these treatments are quite effective, tumours are likely to recur in about 40% of cases. There is a need for additional prostate cancer treatments. To address this need, many experimental therapies are being developed and tested in mice with prostate tumors. This includes the study of aggressive prostate cancer cells such as stem cells, or Tumour Initiating Cells (TICs), or oxygen deprived cells, which may be the ones most likely to re-grow into a tumour or spread throughout the body. Researchers want to try and isolate these special cells from the prostate after surgery to study their features, and to see if they can re-grow as solid tumours in mice. Researchers would like to test whether the prostate cancer stem cells are more resistant or less resistant to treatments. This will allow researchers to study and test new treatments that specifically target resistant and aggressive prostate cancer cells. The investigators hypothesize that marker-defined TIC cells or hypoxic cancer cells have unique genetics in primary prostate cancers and are relatively chemo- and radio-resistant.

Conditions

Prostate Cancer

Keywords

prostate cancer; radical prostatectomy

Outcome Measures

Primary Outcomes (1)

• Quantitation of pimonidazole staining (a.u./cm2) in radical prostatectomy specimens as determinant of biochemical failure

  Radical prostatectomy specimens will stained for pimonidazole uptake using antibody-based immunofluorescence assays

  3 years

Secondary Outcomes (1)

• Quantitation of tumour initial cells by immunohistochemistry (cells/mm2) in radical prostatectomy specimens as determinant of biochemical failure

  3 years

Study Arms (1)

Pimonidazole

OTHER

Drug: Pimonidazole

Interventions

Pimonidazole DRUG

Pimonidazole is to be administered to patients scheduled for radical prostatectomy one day prior to surgery.

Pimonidazole

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Prostate cancer patients with bulky intermediate risk or high-risk disease who have already agreed to undergo an open radical prostatectomy at Princess Margaret Cancer Centre-UHN:
• Clinical stage T2-T3 N0 M0
• Pathology of adenocarcinoma of the prostate AND
• Gleason score 7 with \>/= 50 % biopsies involved with tumour; OR
• Gleason score 8 or above (any percentage of biopsies)

You may not qualify if:

• Patients with clinical T4, N1 or M1 disease
• Patients with histologies other than adenocarcinoma
• Patients unable to ingest pimonidazole tablets

Sponsors & Collaborators

• University Health Network, Toronto: lead

Study Sites (1)

University Health Network

Toronto, Ontario, M5G2M9, Canada

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

pimonidazole

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Alejandro Berlin, MD.

  University Health Network, Toronto

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 12, 2014
• First Posted: March 24, 2014
• Study Start: September 1, 2014
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): January 1, 2028
• Last Updated: June 18, 2024

Record last verified: 2024-06

Locations

CA (1)